Clinical Trial Update: A Safety Study of SEA-BCMA in Patients With Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 safety study of SEA-BCMA in patients with multiple myeloma was terminated. Results were posted on 2024-12-24.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SEA-BCMA

Snippet

Sponsor: Seagen Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2024-12-24